[The Denver shunt in malignant ascites].

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Malignant ascites significantly impacts cancer patient well-being.
• It is often resistant to conventional medical therapies.
• Ascites does not always indicate a preterminal cancer stage.

Observation:

• Medical treatments for malignant ascites yield limited success.
• Immunotherapy with OK-432 requires further validation.
• Peritoneojugular shunts demonstrate promising results for massive, refractory ascites.

Findings:

• Denver shunts may offer advantages over Le Veen shunts for malignant ascites.
• Specific perioperative management strategies are crucial for minimizing shunt-related risks.
• Key measures include catheter placement, fluid management, and infection prophylaxis.

Implications:

• Peritoneojugular shunts provide immediate improvement in nutritional status and quality of life.
• Careful surgical technique and postoperative monitoring reduce complication risks.
• Shunt placement is a viable palliative option, with metastasis risk being minimal.